Table 3

Non-hematological adverse events

Event	Control ASCT (n=5)		IVTRD ASCT (n=4)		EVTRD ASCT (n=5)
Event	All grade	Grade 3 or 4	All grade	Grade 3 or 4	All grade	Grade 3 or 4
Constitutional symptoms
Fatigue	4 (80%)	1 (20%)	0	0	0	0
Fever	3 (60%)	2 (40%)	1 (25%)	1 (25%)	4 (80%)	4 (80%)
Pain	2 (40%)	0	1 (25%)	0	1 (20%)	0
Weight loss	0	0	0	0	1 (20%)	0
Malaise	0	0	0	0	1 (20%)	0
Gastrointestinal disorders
Nausea	2 (40%)	0	1 (25%)	0	1 (20%)	0
Diarrhea	1 (20%)	0	1 (25%)	0	1 (20%)	0
Hepatobiliary disorders
Increased aminotransferase level	1 (20%)	0	0	0	1 (20%)	1 (20%)
Hyperbilirubinemia	1 (20%)	1 (20%)	0	0	1 (20%)	0
Electrolyte disorders
Hypocalcemia	2 (40%)	0	0	0	1 (20%)	0
Hypokalemia	1 (20%)	0	1 (25%)	0	2 (40%)	1 (20%)
Hypophosphatemia	1 (20%)	0	1 (25%)	0	1 (20%)	1 (20%)
Miscellaneous
Hyperglycemia	2 (40%)	1 (20%)	1 (25%)	0	2 (40%)	1 (20%)
Peripheral neuropathy	1 (20%)	0	1 (25%)	0	0	0
Chronic kidney disease	1 (20%)	0	1 (25%)	0	0	0
Bone fracture	0	0	1 (25%)	1 (25%)	0	0
Rash	0	0	0	0	1 (20%)	1 (20%)
Cough	0	0	0	0	1 (20%)	0
Lymphadenitis	0	0	0	0	1 (20%)	0
Hemorrhoids	1 (20%)	0	0	0	0	0

Shown are adverse events (irrespective of the relationship to the study drugs) that were reported in at least one patient.
ASCT, autologous stem cell transplant; EVTRD, ex vivo regulatory T-cell depletion; IVTRD, in vivo regulatory T-cell depletion.